undamentalytics Newsletter
Sign in

Ocular Therapeutix, Inc cash flow statement

In fiscal 2025, Ocular Therapeutix, Inc's operations generated −$205m of cash; it spent $12.0m on capital projects, leaving free cash flow of −$217m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−13−20−34−34−50−49−78−54−66−60−70−135−205−238
Depreciation and amortisation01112233223445
Stock-based pay03567798151718334353
Capital spending0122822114611217
Free cash flow−13−22−36−36−59−51−80−54−67−63−76−136−217−255
Free cash flow after stock pay−13−24−40−42−66−59−89−62−82−80−94−169−260−308
Shares issued—70661296238225——117———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: GOSS vs OCULOCUL vs SIGAOCUL vs TNGXEDIT vs OCUL

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Ocular Therapeutix, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ocular Therapeutix, Inc.